Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.

Abstract: Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).

Abstract: Provided herein are anti-KRas antibodies that bind to mutant KRas-GDP and alkylated mutant KRas-GDP and methods of using the same. Also provide herein are method of screening for KRas inhibitors and methods of measuring binding of KRas to the antibodies described herein.

Abstract: The present invention provides for a method of using CDC2L1, CSNK1A1, GYK, NEK1, PLK1, PRKAR1A, PRKRA, TTBK2 or TTK hedgehog kinase antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells.